

Module 8: ART Resistance and Second Line Regimens



Time: 1 hour, 20 minutes

Session Objectives

By the end of this session, participants will be able to:

- Understand when to switch to a second-line regimen
- Know preferred second-line regimens for adults (including pregnant and breastfeeding women), adolescents, and children
- Describe common drug resistance mutations and how they influence choosing a second-line regimen
- Be familiar with characteristics of the drugs commonly used in second-line regimens

Session Overview



- Management of Treatment Failure
- Second-Line Regimens
- ARV Characteristics
- Common Resistance Mutations
- Third-Line Regimens

Materials Needed





- Slides

55 minute
Lecture




Trainer will:

- Review management of treatment failure, when to switch to second line treatments.
- Describe the preferred and alternative second-line regimens for adults and adolescents, pregnant or breastfeeding women, and children.
- Discuss characteristics of different ARVs in order to understand how the recommendations for second line regimens were devised.
- Review commonly used ARVs for first and second line regimens.
- Discuss common resistance mutations and their effect on regimen selection, including:
 - M184V

	<ul style="list-style-type: none"> ○ Y181C and K103N ○ K65R ○ TAMs ● Discuss different protease and integrase inhibitors. ● Review the formulations available in your country. <p>Break for questions.</p>
<p>5 minute lecture</p> 	<ul style="list-style-type: none"> ● Trainer will summarize key points: <ul style="list-style-type: none"> ○ Avoid premature as well as delayed switching of ART ○ When switching for treatment failure, avoid single agent switches ○ Selection of 2nd and 3rd line regimens must take into account common resistance mutations that arise from 1st line agents.
<p>20 minute Activity</p> 	<p>Facilitator will conduct case two discussions. (See slides and speakers notes for instructions).</p>

Methodologies



Advance Preparation for Trainers



- Trainer must update **slides 8, 10, 27, and 28** with second and third line regimens available in their country.

